Authors: Shrividya Iyer Adam Roughley Alex Rider Gavin TaylorStokes
Publish Date: 2013/09/12
Volume: 22, Issue: 1, Pages: 181-187
Abstract
Disease symptom management in patients with advanced nonsmall cell lung cancer NSCLC is a critical aspect of therapy The main objective of our study was to assess patientreported outcomes and the degree of concordance between physician and patient perceptions of symptom severity in advanced NSCLC in the USAPatients with advanced stage IIIB/IV NSCLC N = 450 were recruited in a nationwide USA lung cancer study Patients and their oncologists completed patient and physician versions of the Lung Cancer Symptom Scale LCSS Patientreported lung cancerspecific quality of life was assessed with the Functional Assessment of Cancer Therapy—Lung FACTL Concordance was assessed using the kappastatistic Regression analysis was performed with FACTL total score as the dependent variable and patientreported LCSS symptom scores as predictorsA high proportion of patients experienced lung cancer symptoms fatigue 100 loss of appetite 97 shortness of breath 95 cough 93 pain 92 and blood in sputum 63 Concordance between physician and patients was lowest for loss of appetite kappa 01701 and greatest for hemoptysis kappa 04586 Loss of appetite β = −0204 p 0001 cough β = −0145 p 001 pain β = −0265 p 0001 and shortness of breath β = −0145 p 001 were found to be significant predictors of the quality of lifeThe Adelphi Lung Cancer Disease Specific Program was supported by Pfizer and other pharmaceutical companies the collection of patientreported outcomes and related analyses was sponsored by Pfizer Inc Editorial assistance was provided by Martin Quinn at ACUMED® Tytherington UK and funded by Pfizer IncShrividya Iyer is an employee of Pfizer Inc Adam Roughley Alex Rider and Gavin TaylorStokes are employees of Adelphi Real World who were paid contractors to Pfizer Inc and were involved in study design data collection analyses and manuscript preparation
Keywords: